The trademark application MABCALIN was filed by Pieris Pharmaceuticals GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on September 20, 2022, and it was registered by office on December 28, 2022 without any oppositions.
It was designated 'Basic Application' for International Application 1711123 at the World Intellectual Property Organization (WIPO).
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:
Chemical preparations for industrial and scientific purposes
Polypeptides and proteins produced by genetic engineering and nucleic acids coding for these, in particular artificial polypeptides and proteins and nucleic acids coding for these
Diagnostic preparations, other than for medical or veterinary purposes.
The mark was filed in class 5 with Pharmaceutical, veterinary and sanitary preparations, in particular artificial polypeptides and proteins and nucleic acids coding for them, in particular for the treatment or prevention of various types of cancers and autoimmune diseases and diagnostic products for medical or veterinary use, in particular for the diagnosis of various types of cancers and autoimmune diseases..
The mark was filed in class 42 with Scientific and industrial research, in particular in the biochemical, diagnostic or pharmaceutical fields and biochemical or pharmaceutical laboratory services..